OneMedNet Corporation, a healthcare software company, provides digital medical image management, exchange, and sharing solutions in the Americas, Europe, and the Middle East.
FAIL · Does not pass the screen
0.69 USD
Price as of 21 Sep 2026Daily close, not a live quoteLast reviewed 47 days ago
Screened 2026-09-21 · the tape above runs as of 02:02 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
Positioning no disclosures inside 60 days, left as found
Options no verdict drawn today, left as found
Ethical does not pass the values gate
Price0.69 USD
Ethical score70.0/100
Our investment reviews on this name
2026-11-01Read Markdown0.69+0.0% to today Markup gives way to Markdown first Markdown read since September
2026-10-02Read Markup0.69+0.0% to today ✓Markdown gives way to Markup after a 27% rise in 13 weeks
2026-07-02Read Markdown0.54+27.0% to today First review on file: Markdown
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
OneMedNet Corp holds its Markdown at $0.69. Consolidating, no directional conviction, held for 4 days.
As held on the ledger · 2026-09-21
Phase
Markdown · caution
Quantitative state
Consolidating, no directional conviction, held for 4 days
Price at the screen
$0.69
Valuation
N/A trailing · N/A forward price to earnings
Values screen
FAIL· score 70.0
Beta
1.14
The Workings
Five Screens, Shown in Full
Does not pass. Accounts receivable
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
26.50%
Below 33%
Interest-bearing debt is just 26.5% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
23.52%
Below 33%
Cash held in interest-bearing accounts and securities is 23.5% of assets, under the one-third limit.
Pass
Receivables
50.21%
Below 49%
Money owed to the company is 50.2% of assets, above the 49% limit.
Fail
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Falls Short, in Plain English
OneMedNet's business is fine, but its receivables are about 50% of its assets, just over the ~49% line, so it does not pass on the financial screens.
Read as at 2026-11-05. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when ONMD's ethical verdict changes
Today ONMD does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
Another profit measure, before interest, tax and non-cash costs: EBITDA.
The risks · The things to watch: it's a small-cap, so the share price can swing harder than the market.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
ONMD trades on NASDAQ. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-11-01Markdown · changed$0.69+0.0%Entry 8
The framework has shifted from markup to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B. Technically it is momentum reading bearish. Over the past year the shares are up 37%. Our forward projection puts the odds of a 10% gain over the next month near 29%. Insiders have been net buyers over the past quarter.
2026-10-21Markup$0.69+0.0%Entry 7
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B. Technically it is momentum reading bearish. Over the past year the shares are up 37%. Our forward projection puts the odds of a 10% gain over the next month near 29%. Insiders have been net buyers over the past quarter.
2026-10-02Markup · changed$0.69+1.5%Entry 6
The framework has shifted from markdown to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 1.5% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it D. Technically it is momentum reading oversold. Over the past year the shares are up 37%. Our forward projection puts the odds of a 10% gain over the next month near 29%. Insiders have been net buyers over the past quarter.
2026-09-08Markdown$0.68+0.0%Entry 5
Our analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D. Technically it is momentum reading oversold. Over the past year the shares are up 37%. Our forward projection puts the odds of a 10% gain over the next month near 29%. Insiders have been net buyers over the past quarter.
2026-08-07Markdown$0.68+25.1%Entry 4
Our analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved up 25.1% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it D. Technically it is momentum reading oversold. Over the past year the shares are up 37%. Our forward projection puts the odds of a 10% gain over the next month near 29%.
2026-07-18Markdown$0.54+0.0%Entry 3
Our analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it D. Technically it is momentum reading oversold. Over the past year the shares are up 37%. Our forward projection puts the odds of a 10% gain over the next month near 29%.
2026-07-03Markdown$0.54+0.0%Entry 2
Our analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows good risk-adjusted returns.
2026-07-02Markdown$0.54Entry 1
Our analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows good risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.